A Global Phase III Trial of SB-030 to Prevent Vein Graft Failure in Peripheral Artery Disease
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs SB 030 (Primary)
- Indications Peripheral arterial disorders; Transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Symic Bio
- 25 Apr 2019 According to a Symic Bio media release, this study is expected to start in 2020.
- 29 May 2017 New trial record
- 22 May 2017 According to a SYMIC Biomedical media release, the company anticipates initiating this trial in 2018.